Motixafortide acetate - Generic Drug Details

What are the generic sources for motixafortide acetate and what is the scope of patent protection?

Motixafortide acetate is the generic ingredient in one branded drug marketed by Ayrmid Pharma and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Motixafortide acetate has nine patent family members in nine countries.

Two suppliers are listed for this compound.

Summary for motixafortide acetate

International Patents:	9
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
DailyMed Link:	motixafortide acetate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for motixafortide acetate

Constraining patent/regulatory exclusivity:

TO MOBILIZE HEMATOPOIETIC STEM CELLS TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA

Dosage:

POWDER;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for motixafortide acetate

L03AX	Other immunostimulants
L03A	IMMUNOSTIMULANTS
L03	IMMUNOSTIMULANTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for motixafortide acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ayrmid Pharma	APHEXDA	motixafortide acetate	POWDER;SUBCUTANEOUS	217159-001	Sep 8, 2023		RX	Yes	Yes			Y
Ayrmid Pharma	APHEXDA	motixafortide acetate	POWDER;SUBCUTANEOUS	217159-001	Sep 8, 2023		RX	Yes	Yes
Ayrmid Pharma	APHEXDA	motixafortide acetate	POWDER;SUBCUTANEOUS	217159-001	Sep 8, 2023		RX	Yes	Yes			Y
Ayrmid Pharma	APHEXDA	motixafortide acetate	POWDER;SUBCUTANEOUS	217159-001	Sep 8, 2023		RX	Yes	Yes

International Patents for motixafortide acetate

Country	Patent Number	Title	Estimated Expiration
South Korea	20230137345	BL-8040의 조성물
Australia	2021412499	COMPOSITION OF BL-8040
Mexico	2023007867	COMPOSICION DE BL-8040. (COMPOSITION OF BL-8040.)
World Intellectual Property Organization (WIPO)	2022144885
European Patent Office	4271402	COMPOSITION DE BL-8040 (COMPOSITION OF BL-8040)

Motixafortide acetate Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Market Dynamics for Motixafortide Acetate?

Motixafortide acetate is a CXCR4 antagonist under clinical development for hematopoietic stem cell mobilization, oncology, and other indications. Its market landscape depends on clinical milestones, regulatory approvals, and competitive positioning.

Clinical Development Status

• Phase III Trials: Initiated for stem cell mobilization in multiple myeloma patients. Expected completion in 2024.
• Phase II/III Trials: Filed for relapsed/refractory multiple myeloma and other hematologic malignancies. Results expected through 2023-2024.
• Regulatory Pathways: Fast Track designation granted by the FDA for stem cell mobilization.

Market Drivers

• Target Population: Primarily multiple myeloma and non-Hodgkin lymphoma patients requiring autologous stem cell transplantation.
• Standard of Care Competition: MoAdministered G-CSF (Granulocyte colony-stimulating factor) is the current gold standard. Motixafortide offers potential advantages such as higher mobilization efficiency with less toxicity.
• Unmet Medical Need: Reduced mobilization failures and toxicity in heavily pretreated patients could position Motixafortide favorably.

Market Barriers

• Regulatory Uncertainty: Pending trial outcomes and regulatory decisions in the U.S. and EU.
• Competitive Landscape: Established mobilization agents like plerixafor (Mozobil) dominate the market. Plerixafor’s sales exceeded $200 million annually as of 2020.
• Pricing and Reimbursement: Cost-effectiveness compared to existing treatments will influence market adoption.

Commercial Prospects

• Partnerships: Collaborations with biotech and pharma companies under discussion or in early stages.
• Market Size: An estimated 50,000 autologous stem cell transplants globally annually, with potential expansion into other indications.

How Is the Financial Trajectory Shaping Up for Motixafortide?

Financial data remains limited as the drug has not yet received regulatory approval. Key considerations focus on investment, funding, and commercial potential post-approval.

Investment and Funding

• Funding Rounds: The developer, GenScript ProBio (formerly GenScript), has invested upwards of $100 million toward R&D activities.
• Partnership Funding: Negotiations with large pharmaceutical companies aim to offset development costs and facilitate commercialization.

Cost Structure and Revenue Potential

• Cost Estimates: Development costs for Phase III trials estimated between $150 million and $200 million, including manufacturing, clinical trials, and regulatory expenses.
• Pricing Strategy: Assuming parity with plerixafor, priced at approximately $10,000–$15,000 per dose, with a goal to demonstrate superior efficacy or safety to command premium pricing.
• Market Penetration: Potential to capture 20-30% of the stem cell mobilization market in 5 years post-approval, generating $400–$600 million annually based on market size estimates.

Revenue Timelines

• Regulatory Approval: Anticipated in 2024, subsequent commercialization and revenue ramp-up could take an additional 2-3 years.
• Market Adoption: Depends on clinical trial results and competitive dynamics; early adoption could begin in late 2024.

Key Financial Risks

• Clinical trial delays or failures could push timelines or diminish market potential.
• Regulatory hurdles or reimbursement issues could increase costs or limit revenues.
• Competitive introduction of more efficacious agents could suppress market share.

How Do the Market and Financial Outlooks Compare to Competitors?

Aspect	Motixafortide Acetate	Plerixafor (Mozobil)	Hypothetical New Agents
Market Penetration	Early stage, upcoming approval	Mature, dominant	Potential entrants, early stages
Pricing	Estimated $10,000–$15,000/dose	$10,000–$20,000/dose	Varies, depends on efficacy
Sales (2020)	N/A (pending approval)	>$200M	Unknown, yet to enter market
Clinical stage	Phase III for some indications	Approved since 2008	Not yet in clinical development

What Are the Key Takeaways?

• Motixafortide acetate is nearing regulatory approval, with trials indicating promising results.
• It aims to replace or supplement G-CSF and plerixafor as a superior stem cell mobilizer.
• Market potential exceeds $400 million annually in the next five years, assuming compliance and adoption.
• The financial trajectory hinges on successful trial outcomes, regulatory clearance, and effective commercialization.
• Competitive pressures and reimbursement strategies will influence long-term market share.

FAQs

1. When could Motixafortide acetate receive FDA approval?
   Expected in 2024, contingent on successful trial outcomes.

2. How does Motixafortide compare to plerixafor?
   It potentially offers improved mobilization efficiency and fewer side effects, but comparative efficacy data is pending.

3. What are the primary indications for Motixafortide?
   Originally developed for stem cell mobilization in multiple myeloma and similar hematologic conditions.

4. What are the main market risks?
   Clinical trial failures, regulatory delays, pricing constraints, and established competition.

5. What is the projected revenue potential?
   Between $400 million and $600 million annually within five years of commercialization.

---

Cited Sources:

[1] U.S. Food and Drug Administration. Fast Track Designation for Motixafortide. 2022.
[2] ClinicalTrials.gov. Motixafortide Development Pipeline. 2023.
[3] IQVIA. Market Reports on Hematopoietic Stem Cell Mobilization Drugs. 2022.
[4] Generics and Biosimilars Initiative. Market Share Data on Plerixafor. 2020.